Undp South Sudan

Undp South Sudan is a procurement entity operating under the United Nations Development Programme (UNDP) in South Sudan. As part of the UNDP's mission, it is responsible for sourcing and importing pharmaceutical products to support the country's healthcare system. The organization plays a pivotal role in ensuring the availability of essential medicines and medical supplies, particularly for programs targeting diseases such as HIV/AIDS and tuberculosis. By managing the procurement process, Undp South Sudan contributes to the effective delivery of healthcare services across the nation.

Undp South Sudan's distribution network is centered around key facilities, notably the Riverside Warehouse in Gumbo, Juba. This warehouse serves as a critical hub for storing and managing pharmaceutical supplies, including HIV/AIDS and tuberculosis medications. The facility employs advanced inventory management systems, such as mSupply, to monitor stock levels, manage orders, and ensure the safe storage of medicines. Additionally, the warehouse is equipped with cold chain storage to maintain the efficacy of temperature-sensitive products. Through this infrastructure, Undp South Sudan ensures the timely and efficient distribution of medical supplies to health facilities across the country.

In South Sudan's pharmaceutical supply chain, Undp South Sudan functions as a primary wholesaler and distributor. It is responsible for the procurement, storage, and distribution of essential medicines and medical supplies to various health facilities nationwide. By managing these operations, Undp South Sudan ensures that healthcare providers have access to the necessary pharmaceuticals to deliver effective patient care. Its role is crucial in maintaining the continuity of treatment programs and supporting the overall health infrastructure in the country.

Undp South Sudan's procurement strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports sourced from India. The total import value from India amounts to $1.3 million USD, encompassing 32 shipments and 63 unique formulations. This concentration indicates a strategic choice to leverage India's established pharmaceutical manufacturing capabilities and cost-effectiveness. The consistent shipment data suggests a stable and reliable relationship between Undp South Sudan and its Indian suppliers, which is essential for maintaining a steady supply of essential medicines.

The resilience of Undp South Sudan's supply chain is bolstered by its diversified supplier base, comprising nine unique Indian pharmaceutical companies. This diversity mitigates the risks associated with over-reliance on a single supplier and enhances the stability of the supply chain. The inclusion of multiple suppliers also provides flexibility in sourcing and the ability to adapt to changing market conditions. However, the supply chain's resilience is contingent upon the reliability and compliance of these suppliers with international quality standards, as well as the robustness of the logistics infrastructure facilitating the importation process.

Undp South Sudan's sourcing pattern, characterized by a concentrated focus on Indian suppliers, positions it to benefit from competitive pricing and a consistent supply of quality pharmaceuticals. For Indian exporters, this presents an opportunity to strengthen existing partnerships and explore avenues for expanding their product offerings to meet the evolving needs of the South Sudanese market. Additionally, the established procurement processes and quality standards adhered to by Undp South Sudan provide a framework for Indian exporters to align their products and services, thereby enhancing their competitiveness in the market.

The South Sudan Drug and Food Control Authority (SSDFCA) is the primary regulatory body overseeing the quality, safety, and efficacy of pharmaceuticals within the country. Established under the Drug and Food Control Authority Act, 2012, the SSDFCA is responsible for regulating the importation, manufacture, distribution, advertisement, and use of pharmaceutical products. The authority collaborates with the Ministry of Health, Ministry of Commerce, Industry and Investment, and other relevant agencies to enforce its mandate, ensuring that all pharmaceutical products meet national and international standards.

Importers of pharmaceutical products into South Sudan are required to obtain a License B from the SSDFCA, which authorizes them to import, wholesale, and distribute pharmaceutical products. Applicants must demonstrate financial capacity, provide suitable premises, and employ qualified professionals, such as pharmacists, to meet the regulatory requirements. Additionally, the SSDFCA mandates that imported pharmaceutical products comply with recognized Good Manufacturing Practice (GMP) standards, such as those from the European Union (EU GMP), World Health Organization (WHO GMP), or Pharmaceutical Inspection Co-operation Scheme (PIC/S). This ensures that imported medicines are of high quality and safe for public use.

Imported pharmaceutical products must adhere to specific quality and labeling standards set by the SSDFCA. All regulated products are required to be labeled with their generic or international non-proprietary names, in addition to the proprietary name, to ensure clarity and prevent confusion. The labeling must also include tamperproof and indelible imprints of manufacturing and expiry dates, batch or lot numbers, and other information as prescribed by regulations. These requirements are designed to ensure the safety, efficacy, and traceability of pharmaceutical products within South Sudan. (extranet.who.int)

Between 2024 and 2026, South Sudan has implemented several policy changes affecting pharmaceutical imports. Notably, in July 2025, Gavi, the Vaccine Alliance, provided $2.6 million to strengthen South Sudan's supply chain system. This funding supports the expansion of cold-chain capacity and dry storage at key facilities, enhancing the country's ability to manage and distribute essential medicines effectively. Such initiatives reflect a commitment to improving the pharmaceutical supply chain infrastructure and ensuring the availability of quality medicines to the population.

Undp South Sudan's focus on importing advanced antibiotics, specifically sulfamethoxazole and trimethoprim, indicates a strategic approach to addressing prevalent infectious diseases within the country. The substantial import values of these products, each amounting to $636,000 USD, underscore their critical role in the national healthcare strategy. The decision to concentrate on these therapeutic areas is likely driven by the high incidence of bacterial infections and the need for effective antimicrobial treatments to improve public health outcomes.

Undp South Sudan's sourcing strategy emphasizes the procurement of generic pharmaceutical formulations, primarily from India. This approach leverages India's robust pharmaceutical manufacturing sector, known for producing high-quality generics at competitive prices. The focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), aligns with the immediate needs of the South Sudanese healthcare system, ensuring the availability of ready-to-use medicines for patients.

By importing and distributing essential medicines, Undp South Sudan serves a critical role in the healthcare sector, positioning itself as a key supplier to government health facilities, hospitals, and clinics. Its operations support the public health infrastructure, ensuring that healthcare providers have access to necessary pharmaceuticals to deliver effective patient care. This positioning underscores Undp South Sudan's commitment to enhancing the health and well-being of the South Sudanese population.

There is a realistic opportunity for new Indian suppliers to engage with Undp South Sudan, particularly those offering high-quality generic formulations that meet international GMP standards. The existing concentration on a limited number of products suggests potential gaps in the product portfolio, which new suppliers could fill. Additionally, the ongoing strengthening of the pharmaceutical supply chain in South Sudan presents an opportunity for suppliers to establish long-term partnerships and contribute to the country's health sector development.

Indian exporters seeking to supply Undp South Sudan must ensure that their products comply with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, they must adhere to the labeling requirements set by the SSDFCA, including the use of generic or international non-proprietary names and the inclusion of manufacturing and expiry dates, batch numbers, and other prescribed information. Establishing a partnership with Undp South Sudan also requires a thorough understanding of the regulatory framework governing pharmaceutical imports into South Sudan and a commitment to maintaining high-quality standards.

To establish a relationship with Undp South Sudan, Indian exporters should begin by ensuring their products meet the necessary GMP standards and labeling requirements. Engaging with the SSDFCA to obtain the required import licenses and approvals is a crucial step. Participating in UNDP procurement processes, which may include responding to Requests for Proposals (RFPs) or Invitations to Bid (ITBs), is essential. Building a strong understanding of the local market dynamics and demonstrating a commitment to quality and reliability will enhance the prospects of successful collaboration with Undp South Sudan.